The Live Nagpur
  • Nagpur City
  • Nagpur Education
  • Nagpur Sports
  • Business
  • Featured
  • Crime
  • Entertainment & Lifestyle
  • Health & Wellness
  • Nation
  • Politics
  • Trending
  • Vidarbha
  • Obituary

The Live Nagpur


  • Home
  • City
  • Politics
  • Business
  • Education
  • Entertainment
  • Sports
  • Health
  • Crime
  • Forest
  • Featured
  • Vidarbha
Health & Wellness

Phase 3 Clinical Trial of COVAXIN shows 81% efficacy

by TLN Team August 3, 2021August 3, 2021
written by TLN Team August 3, 2021August 3, 2021
Phase 3 Clinical Trial of COVAXIN shows 81% efficacy

The Phase 3 result of the COVAXIN has shown an interim vaccine efficacy of 81% in preventing Covid-19.

The Phase 3 trial was initiated in mid-November 2020, which was conducted in a total of 25,800 individuals across 21 sites. The interim efficacy trend of 81%, analyzed as per the protocol approved by the DCGI, puts it at par with other global front-runner vaccines.

“The bench-to-bedside journey of completely indigenous COVID-19 vaccine in less than 8 months’ time showcases the immense strength of Atmanirbhar Bharat [self-reliant India] to fight the odds and stand tall in the global public health community. It is also a testament to India’s emergence as a global vaccine superpower,” said Dr. Balram Bhargava, Director General, ICMR.

The COVAXIN is the first COVID-19 vaccine that has been developed completely in India. In March 2020, following the successful isolation of the SARS CoV-2 virus at ICMR-National Institute of Virology (NIV), ICMR entered into a public-private partnership with BBIL to develop the virus isolate into an effective vaccine candidate.

ICMR-NIV characterized the vaccine developed by BBIL through in-vitro experiments and electron microscopy studies.

Pre-clinical studies in small animals and hamsters showed promising results in terms of safety and immunogenicity. Further studies conducted in rhesus macaques also established remarkable safety and protective efficacy of COVAXIN. Phase 1 and Phase 2 clinical trials conducted in 755 participants demonstrated high safety profile of the candidate vaccine with seroconversion rates of 98.3% and 81.1% on day 56 and 104 respectively.

COVAXIN has been developed on the WHO prequalified vero cell platform, which is globally recognized with a well-established track record of safety. COVAXIN’s ability to neutralize UK variant strain of SARS-CoV-2 has also recently been established. “The development and deployment of COVAXIN ensures that India has a powerful weapon in its arsenal in a continually evolving pandemic situation and will go a long way in helping us win the war against COVID-19. The need of the hour is to ensure that people in India continue to receive the vaccine and break the chain of virus transmission,” said Dr. Samiran Panda, Head, Epidemiology and Communicable Disease, ICMR and Director, National AIDS Research Institute.

0 comment
FacebookTwitterLinkedin
TLN Team

previous post
CBSE Class X result declared, 99.04% pass percent
next post
UGC declares 24 fake institutes, one from Nagpur

You may also like

‘Lizard in a cold drink,’ AMC closes McDonald’s...

May 23, 2022

“Massage Therapy by Ashadeep is a step towards...

May 16, 2022

Retirement age limit of Public health docs reduced...

May 13, 2022

Diet counselling for children with special needs on...

May 12, 2022

Technology can make India self-reliant: Dr Sonde

May 12, 2022

Taking Care of Nutrition Needs of Kids with...

May 11, 2022

Knee replacement surgeries started under the MJPJAY scheme...

May 11, 2022

Vaccination: The Key to Preventing Influenza Infections amongst...

April 27, 2022

DCGI grants emergency use of Covaxin, Corbevax vaccine...

April 26, 2022

Wockhardt Hospital’s Personalized Cancer care bringing a revolutionary...

April 23, 2022

Trending News

  • City’s Pohewala enters first phase of ‘Shark Tank India S2’

    May 24, 2022
  • Three injured after falling from mid-air during paprasailing

    May 23, 2022
  • RTMNU exam in MCQ format off-line mode

    May 20, 2022
  • Umran Malik becomes youngest bowler to take 20 wickets in an IPL

    May 19, 2022
  • Mini MBA course in just one rupee, know how

    May 17, 2022

Important Links

  • Politics
  • Crime
  • Business
  • Education
  • Entertainment
  • Sports

Available on Playstore & Coming Soon on Appstore

Search

August 2021
M T W T F S S
« Jul   Sep »
 1
2345678
9101112131415
16171819202122
23242526272829
3031  

Sign-Up Form

Subscribe my Newsletter for new blog posts, tips & new photos. Let's stay updated!

Footer Logo
  • Nagpur City
  • Nagpur Education
  • Nagpur Sports
  • Business
  • Featured
  • Crime
  • Entertainment & Lifestyle
  • Health & Wellness
  • Nation
  • Politics
  • Trending
  • Vidarbha
  • Obituary
  • Privacy Policy
  • Disclaimer
  • Cookie Policy
  • Terms Of Use
  • Advertise with Us
  • Work with us
  • Contact Us

© 2020 - The Live Nagpur . All Rights Reserved.